167 related articles for article (PubMed ID: 16882552)
21. The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
Fisher SJ; Swaan PW; Eddington ND
J Pharmacol Exp Ther; 2010 Jan; 332(1):326-33. PubMed ID: 19820208
[TBL] [Abstract][Full Text] [Related]
22. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies.
Yang T; Hussain A; Paulson J; Abbruscato TJ; Ahsan F
Pharm Res; 2004 Jul; 21(7):1127-36. PubMed ID: 15290851
[TBL] [Abstract][Full Text] [Related]
23. The effect of delta G on the transport and oral absorption of macromolecules.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharm Sci; 2004 May; 93(5):1310-9. PubMed ID: 15067707
[TBL] [Abstract][Full Text] [Related]
24. N-sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules.
Thanou M; Henderson S; Kydonieus A; Elson C
J Control Release; 2007 Feb; 117(2):171-8. PubMed ID: 17184870
[TBL] [Abstract][Full Text] [Related]
25. Modulation of intestinal permeability: an innovative method of oral drug delivery for the treatment of inherited and acquired human diseases.
Fasano A
Mol Genet Metab; 1998 May; 64(1):12-8. PubMed ID: 9682213
[TBL] [Abstract][Full Text] [Related]
26. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T; Kanazawa T; Takashima Y; Okada H
Chem Pharm Bull (Tokyo); 2011; 59(2):196-201. PubMed ID: 21297299
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats.
Furubayashi T; Kamaguchi A; Kawaharada K; Masaoka Y; Kataoka M; Yamashita S; Higashi Y; Sakane T
Biol Pharm Bull; 2007 Mar; 30(3):608-11. PubMed ID: 17329868
[TBL] [Abstract][Full Text] [Related]
28. In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer.
Rama Prasad YV; Minamimoto T; Yoshikawa Y; Shibata N; Mori S; Matsuura A; Takada K
Int J Pharm; 2004 Mar; 271(1-2):225-32. PubMed ID: 15129989
[TBL] [Abstract][Full Text] [Related]
29. ZOT-derived peptide and chitosan functionalized nanocarrier for oral delivery of protein drug.
Lee JH; Sahu A; Choi WI; Lee JY; Tae G
Biomaterials; 2016 Oct; 103():160-169. PubMed ID: 27380442
[TBL] [Abstract][Full Text] [Related]
30. Zonula occludens toxin as a new promising adjuvant for mucosal vaccines.
De Magistris MT
Vaccine; 2006 Apr; 24 Suppl 2():S2-60-1. PubMed ID: 16823929
[TBL] [Abstract][Full Text] [Related]
31. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharmacol Exp Ther; 2005 Jan; 312(1):199-205. PubMed ID: 15448170
[TBL] [Abstract][Full Text] [Related]
32. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro.
Fasano A; Fiorentini C; Donelli G; Uzzau S; Kaper JB; Margaretten K; Ding X; Guandalini S; Comstock L; Goldblum SE
J Clin Invest; 1995 Aug; 96(2):710-20. PubMed ID: 7635964
[TBL] [Abstract][Full Text] [Related]
33. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
34. The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway.
Fasano A; Uzzau S; Fiore C; Margaretten K
Gastroenterology; 1997 Mar; 112(3):839-46. PubMed ID: 9041245
[TBL] [Abstract][Full Text] [Related]
35. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain.
Di Pierro M; Lu R; Uzzau S; Wang W; Margaretten K; Pazzani C; Maimone F; Fasano A
J Biol Chem; 2001 Jun; 276(22):19160-5. PubMed ID: 11278543
[TBL] [Abstract][Full Text] [Related]
36. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis.
Boirivant M; Amendola A; Butera A; Sanchez M; Xu L; Marinaro M; Kitani A; Di Giacinto C; Strober W; Fuss IJ
Gastroenterology; 2008 Nov; 135(5):1612-1623.e5. PubMed ID: 18765239
[TBL] [Abstract][Full Text] [Related]
37. Intestinal absorption of low molecular weight heparin in animals and human subjects.
Nissan A; Ziv E; Kidron M; Bar-On H; Friedman G; Hyam E; Eldor A
Haemostasis; 2000; 30(5):225-32. PubMed ID: 11251329
[TBL] [Abstract][Full Text] [Related]
38. A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine.
Gupta V; Hwang BH; Doshi N; Mitragotri S
J Control Release; 2013 Dec; 172(2):541-9. PubMed ID: 23680288
[TBL] [Abstract][Full Text] [Related]
39. Enhanced gastrointestinal passive paracellular permeability contributes to the obesity-associated hyperoxaluria.
Bashir M; Meddings J; Alshaikh A; Jung D; Le K; Amin R; Ratakonda S; Sharma S; Granja I; Satti M; Asplin J; Hassan H
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G1-G14. PubMed ID: 30307745
[TBL] [Abstract][Full Text] [Related]
40. In vitro cell culture evaluation and in vivo efficacy of amphiphilic chitosan for oral insulin delivery.
Shelma R; Sharma CP
J Biomed Nanotechnol; 2013 Feb; 9(2):167-76. PubMed ID: 23627043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
